Gram-positive bacterial infections: Research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group

Clinical Infectious Diseases

Volumn 64, Issue , 2017, Pages S24-S29

  Doernberg, Sarah B ^a   Lodise, Thomas P ^b   Thaden, Joshua T ^c   Munita, Jose M ^d,e   Cosgrove, Sara E ^f   Arias, Cesar A ^d   Boucher, Helen W ^g   Corey, G Ralph ^c   Lowy, Franklin D ^h   Murray, Barbara ^d   Miller, Loren G ⁱ   Holland, Thomas L ^c,j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UNIVERSIDAD DEL DESARROLLO   (Chile)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g TUFTS MEDICAL CENTER   (United States)

^h NONE   (United States)

ⁱ HARBOR UCLA MEDICAL CENTER   (United States)

^j DUKE CLINICAL RESEARCH INSTITUTE   (United States)

more..

Author keywords

Bloodstream infection; Clostridium difficile infection; Gram positive bacteria; Staphylococcus aureus; Vancomycin resistant enterococci

Indexed keywords

DAPTOMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BLOODSTREAM INFECTION; GRAM POSITIVE INFECTION; HEALTH CARE ORGANIZATION; HUMAN; MEDICAL RESEARCH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEONATAL INTENSIVE CARE UNIT; NONHUMAN; PRIORITY JOURNAL; VANCOMYCIN RESISTANT ENTEROCOCCUS; DRUG EFFECTS; GRAM POSITIVE BACTERIUM; LEADERSHIP; MICROBIOLOGY; ORGANIZATION AND MANAGEMENT; RESEARCH; TRENDS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LEADERSHIP; RESEARCH;

EID: 85033445969     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw828     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/. Accessed 10 August 2016.
2. Fowler VG Jr, Boucher H W, Corey GR, et al; Staphylococcus aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65.
3. Holland TL, Arnold C, Fowler VG Jr. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA 2014;312:1330-41.
4. McKinnell JA, Arias CA. Editorial commentary: linezolid vs daptomycin for vancomycin-resistant enterococci: the evidence gap between trials and clinical experience. Clin Infect Dis 2015;61:879-82.
5. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825-34.
6. Chambers HF, Bartlett JG, Bonomo RA, et al. Antibacterial resistance leadership group: open for business. Clin Infect Dis 2014;58:1571-6.
7. Lodise T P, Drusano GL, Zasowski E, et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis 2014;59:666-75.
8. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004;43:925-42.
9. Kullar R, Leonard SN, Davis SL, et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy 2011;31:441-8.
10. Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2013;57:1654-63.
11. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. Clin Infect Dis 2011;52:969-74.
12. Huvane J, Komarow L, Hill C, et al. Fundamentals and catalytic innovation: the Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S18-23.
13. Cross HR, Harris A, Arias RM, et al. Transforming concepts into clinical trials and creating a multisite network: the Leadership and Operations Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S8-12.
14. Liu C, Bayer A, Cosgrove SE, et al; Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-55.
15. Paul M, Bishara J, Yahav D, et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ 2015;350:h2219.
16. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005;56:923-9.
17. Heldman AW, Hartert T V, Ray SC, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996;101:68-76.
18. Jernigan JA, Farr BM. Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis. Ann Intern Med 1993;119:304-11.
19. DiNubile MJ. Noninferior antibiotics: when is "not bad" "good enough"? Open Forum Infect Dis 2016;3:ofw110.
20. Evans SR, Follmann D. Comment: fundamentals and innovation in antibiotic trials. Stat Biopharm Res 2015;7:331-6.
21. Evans SR, Rubin D, Follmann D, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis 2015;61:800-6.
22. Doernberg S, Gouskova N, Evans S, et al. BAC DOOR: a clinician ranking exercise for better S. aureus bacteremia trial design. In: IDWeek 2016. New Orleans, LA, 26-30 October 2016.
23. Chopra V, Anand S, Krein SL, Chenoweth C, Saint S. Bloodstream infection, venous thrombosis, and peripherally inserted central catheters: reappraising the evidence. Am J Med 2012;125:733-41.
24. Burke RE, Halpern MS, Baron EJ, Gutierrez K. Pediatric and neonatal Staphylococcus aureus bacteremia: epidemiology, risk factors, and outcome. Infect Control Hosp Epidemiol 2009;30:636-44.
25. Carey AJ, Duchon J, Della-Latta P, Saiman L. The epidemiology of methicillin-susceptible and methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit, 2000-2007. J Perinatol 2010;30:135-9.
26. Marchant EA, Boyce GK, Sadarangani M, Lavoie PM. Neonatal sepsis due to coagulase-negative staphylococci. Clin Dev Immunol 2013;2013:586076.
27. Thaden JT, Ericson JE, Cross H, et al; Antibacterial Resistance Leadership Group. Survival benefit of empirical therapy for Staphylococcus aureus bloodstream infections in infants. Pediatr Infect Dis J 2015;34:1175-9.
28. Ericson JE, Thaden J, Cross HR, et al; Antibacterial Resistance Leadership Group. No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants. Pediatr Infect Dis J 2015;34:371-5.
29. Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. Mayo Clin Proc 2006;81:529-36.
30. Balli E P, Venetis CA, Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother 2014;58:734-9.
31. Whang DW, Miller LG, Partain NM, McKinnell JA. Systematic re view and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother 2013;57:5013-8.
32. Chuang YC, Wang JT, Lin H Y, Chang SC. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis. BMC Infect Dis 2014;14:687.
33. Shukla BS, Shelburne S, Reyes K, et al. Influence of minimum inhibitory concentration in clinical outcomes of Enterococcus faecium bacteremia treated with daptomycin: is it time to change the breakpoint? Clin Infect Dis 2016;62:1514-20.
34. Munita JM, Panesso D, Diaz L, et al. Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother 2012;56:4354-9.
35. Munita JM, Mishra NN, Alvarez D, et al. Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions. Clin Infect Dis 2014;59:1277-80.
36. Centers for Disease Control and Prevention. Antibiotic/antimicrobial resistance: biggest threats. Available at: http://www.cdc.gov/drugresistance/biggest-threats.html. Accessed 10 August 2016.
37. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38:994-1000.
38. Florescu I, Beuran M, Dimov R, et al; 307 Study Group. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008;62:i17-28.